Evidence map›Paper›PMID 25732229›Full record

ArticleAmerican journal of hematology2015

The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia.

Juan Ouyang, Maitrayee Goswami, Guilin Tang, Jie Peng, Farhad Ravandi, Naval Daver, Mark Routbort, Sergej Konoplev, Pei Lin, L Jeffrey Medeiros and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of hematology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. iAMP21 in acute myeloid leukemia is associated with complex karyotype, TP53 mutation and dismal outcome.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020
    Article
  6. Review
  7. MRD evaluation of AML in clinical practice: are we there yet?Hematology. American Society of Hematology. Education Program · 2019
    Review
  8. Article
  9. Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019
    Article
  10. Review
  11. Article
  12. Article
  13. Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Juan OuyangDepartment of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, Texas.
Maitrayee GoswamiDepartment of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, Texas.
Guilin TangDepartment of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, Texas.
Jie PengDepartment of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, Texas.
Farhad RavandiDepartment of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, Texas.
Naval DaverDepartment of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, Texas.
Mark RoutbortDepartment of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, Texas.
Sergej KonoplevDepartment of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, Texas.
Pei LinDepartment of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, Texas.
L Jeffrey MedeirosDepartment of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, Texas.
Jeffrey L JorgensenDepartment of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, Texas.
Sa A WangDepartment of Hematopathology, the University of Texas MD Anderson Cancer Center, Houston, Texas.
The University of Texas MD Anderson Cancer Center · USThe First Affiliated Hospital, Sun Yat-sen University · CN

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Kathrin Milbury · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

In a patient with acute myeloid leukemia (AML) following therapy, finding ≥5% bone marrow (BM) blasts is highly concerning for residual/relapsed disease. Over an 18-month period, we performed multicolor flow cytometry immunophenotyping (MFC) for AML minimal residual disease on >4,000 BM samples, and identified 41 patients who had ≥5% myeloblasts by morphology but negative by MFC. At the time of a negative MFC study, an abnormal cytogenetic study converted to negative in 14 patients and remained positive at a low level (2.5-9.5%) by fluorescence in situ hybridization in 3 (14%), of the latter, abnormalities subsequently disappeared in the repeated BM in 2 patients. Positive pretreatment mutations, including FLT3, NPM1, IDH1, CEBPA, became negative in all 10 patients tested. Of the seven patients with favorable cytogenetics, PML/RARA, CBFB-MYH11 or RUNX1-RUNX1T1 fusion transcripts were detected at various levels in six patients but all patients remained in complete remission. With no additional chemotherapy given, 39 patients had BM repeated (median 2 weeks, range <1-21), and all cases showed <5% BM blasts and a continuously negative MFC. In the end of follow-up (median 10 months, range 1-22), 13 patients experienced relapse, 12/13 showing clonal cytogenetic evolution/switch and 11 demonstrating major immunophenotypic shifts. We conclude that MFC is useful in identifying a regenerating BM sample with ≥5% BM blasts that would otherwise be scored as positive using standard morphologic examination. We believe this conclusion is supported by the changes in molecular cytogenetic status and the patient clinical follow-up data.

Indexed as

Flow CytometryLeukemia, Myeloid, AcuteMutationNeoplasm ProteinsAdolescentAdultAgedAged, 80 and overBone MarrowBone Marrow CellsChildChild, PreschoolFemaleFollow-Up StudiesHumansInfantNeoplasm ProteinsNPM1 protein, humanNucleophosmin

Identifiers

PMID25732229
PMCPMC5594737
OpenAlexW1747932062

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.